TxCell achieves positive results for Col-Treg in a model of autoimmune uveitis
TxCell SA announced that TxCell researchers have achieved positive results for Col-Treg, its second product candidate from its ASTrIA platform, in a model of autoimmune uveitis, a leading cause of blindness with very limited treatment options.
TxCell demonstrated clear efficacy and tolerability of Col-Treg for the treatment of autoimmune uveitis. The results generated in the model include pharmacodynamic and pharmacokinetic data that shows a reduction in the severity of uveitis on clinical and histologic measures. In addition, TxCell has also generated GLP toxicology results that indicate a good safety profile for Col-Treg. TxCell intends to submit these results for publication in a recognized, peer-reviewed journal.
Autoimmune uveitis has been characterised as a disease in which there is a dysfunction of the T regulatory cell compartment of the immune system. Recent scientific studies have demonstrated that the administration or induction of regulatory T (Treg) cells in vivo can be used as therapeutic tools for the control of ocular inflammation, including that seen in autoimmune uveitis. As a result, TxCell is developing Col-Treg as a personalized T cell immunotherapy based on the regulatory properties of autologous collagen-II specific regulatory T lymphocytes. Col-Treg is specifically designed to exert a multi-target, multi-mechanism suppressive and anti-inflammatory action locally in the eye upon recognition of collagen-II, a protein present in the vitreous body of both the eye and retina.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Antisoma initiates phase IIb trial of AS1411 in acute myeloid leukaemia
ITI Life Sciences Seeks to Fund Innovative R&D Programme in Synthetic Biology, focusing on Gene & Genome Synthesis and Assembly
GE Healthcare and BAC start collaboration in biopharmaceutical purification
CuraGen and TopoTarget Initiate Phase Ib Clinical Trial with PXD101 for Advanced Colorectal Cancer - Proof-of-Concept Trial Evaluating PXD101 Combination Therapy with 5- fluorouracil for Advanced Solid Tumors and Colorectal Cancer
Vernalis extends cancer research collaboration with Novartis Institutes for BioMedical Research - Joint research and development programme on Hsp90, a target implicated in a number of different cancers - Vernalis to receive a $1.5 million signature fee - Novartis to make an investment in new Vernalis shares of approximately ?5 million
Kiadis Pharma receives two orphan drug designations for Reviroc from the FDA
